Search results
Showing 101 to 150 of 8174 results
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a role in...
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together...
NICE is trialling an innovative new approach to the way digital products, devices and diagnostics are assessed.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
The different types of health, public health and social care information provided by NICE.
NICE guidance that could generate cost savings.
Biosimilar technologies: NICE position statement - information for the public
Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...
NICE has been collaborating with NHS England on the Chemotherapy Dose Standardisation initiative which has been developed by the Medicines...
There are 2 different points of the lifecycle of a NICE Technology Appraisal at which consideration of reference to or inclusion of a biosimilar is...
Patients taking part in clinical trials may receive drugs which have been evaluated by NICE technology appraisal guidance. Queries have been raised...
On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar
Tools and resources to help you implement guidance and quality standards at work.
We work with organisations to help to put our guidance into practice. We work with NHS, local authority and other organisations in their area,...
NICE transparency of spend
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
Role and responsibilities of the National Institute of Health and Care Excellence
NICE guidance accredited decisions - status and term dates of NICE accredited guidance producers.
Join Nice's Public Involvement Programme expert panel
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals. Read the appeal panel
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
NICE committee vacancies for health, social care and other professionals and practitioners
We're looking for health, social care and other professionals and practitioners to take an active role in producing a NICE guideline or quality standard.
NICE committee vacancies for patients, service users, carers and lay people
// Return to the our committees home page .
The resources in this section have been developed to help you deliver services to your users. Buy books, journals and databases Use the NICE...
The NICE Electronic and Print Content Framework Agreement - enables the NHS and other health and social care related organisations to buy medical and healthcare related content.
We're looking for healthcare professionals and lay people to chair our guideline committees.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...
Our guidance users tell us they want us to more rapidly update the topics that matter most to the health and care system. We've listened, so we're...
A quick, easy way to access key information from NICE on social care topics.
Biographies and registered interests for members of the Technology Appraisal Committee A
Our role in the Innovative Licensing and Access Pathway (ILAP)
The Innovative Licensing and Access Pathway (ILAP) aims to streamline patient access to safe, financially sustainable and innovative medicines. It's...
NICE advice is a support service for pharmaceutical and healthtech companies seeking to enter the NHS market.
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
NICE recommends better targeting of antibiotics for suspected sepsis to ensure the right people receive treatment
How to submit a new medical technology to NICE for guidance
Our medical technologies guidance evaluates new, innovative medical devices and diagnostics.
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
NICE is unable to make a recommendation on treosulfan (Trecondi) with fludarabine before allogeneic stem cell transplant for babies, children and young people aged 1 month to 17 years with non-malignant diseases. This is because Medac Pharma did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA945
An advisory service from the UK’s National Institute for Health and Care Excellence to help other countries improve their nation’s health and wellbeing
CKS end user licence agreement
Find out more about the diagnostics advisory committee members by reading their biographies. Dr Brian Shine (chair) Biography Brian is a
Our policies and procedures on topics including declarations of interest, gifts and hospitality, complaints, and more.